Recipharm and LIDDS Establish Industrial Manufacturing Capabilities for Prostate Cancer Drug

Jul 25, 2017
By BioPharm International Editors

Recipharm, a contract development and manufacturing organization (CDMO), and LIDDS have together set up a manufacturing line for LIDDS’ novel prostate cancer drug, Liproca Depot, which contains 2-hydroxyflutamide, at Recipharm’s facility in Solna, Sweden.

The manufacturing line is dedicated to the first product based on LIDDS’ innovative NanoZolid technology, which provides localized controlled release that can be sustained for up to six months. NanoZolid can integrate both small- and large-molecule drugs. Clinical trial material has already been produced, and the facility is ready for future commercial manufacturing of Liproca Depot or other pharmaceutical formulations based on the NanoZolid technology. The manufacturing line has been adapted for GMP production and uses a unique process invented by LIDDS that uses equipment that is new to the pharmaceutical industry.

”With the successful manufacturing performed at Recipharm, LIDDS can offer license agreements for Liproca Depot with the advantage of having validated production in place, saving both time and money for pharma companies. In addition, we now have an established manufacturing facility ready for other NanoZolid projects,” says Monica Wallter CEO of LIDDS.

Source: Recipharm

native1_300x100
lorem ipsum